Immix Biopharma Completes Enrollment for BLA-Enabling AL Amyloidosis Trial NEXICART-2; Topline Results Expected Q3 2026
Summary
Immix Biopharma announced the completion of enrollment for its pivotal BLA-enabling NEXICART-2 trial evaluating NXC-201 for relapsed/refractory AL Amyloidosis. This significant operational milestone confirms the trial is on schedule, with topline results now expected in Q3 2026, paving the way for a subsequent Biologics License Application (BLA) submission and planned commercial launch. The company also strengthened its leadership by onboarding a new Chief Medical Officer with extensive experience in BLA submissions for major pharmaceutical companies. This development is highly positive, de-risking the clinical timeline for NXC-201, which already holds FDA Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations. Traders should now monitor for the Q3 2026 data readout as the next major catalyst for the stock.
At the time of this announcement, IMMX was trading at $8.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $431.7M. The 52-week trading range was $1.34 to $11.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.